Zacks Investment Research upgraded shares of Alcobra Ltd. (NASDAQ:ADHD) from a hold rating to a buy rating in a report issued on Wednesday. The firm currently has $1.25 price target on the biotechnology company’s stock.
According to Zacks, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. “
Several other equities analysts have also weighed in on ADHD. Roth Capital lowered Alcobra from a buy rating to a neutral rating and cut their target price for the company from $4.00 to $1.00 in a report on Friday, September 29th. Jefferies Group LLC restated a hold rating and set a $1.25 target price on shares of Alcobra in a report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $1.55.
Shares of Alcobra (NASDAQ:ADHD) opened at 1.05 on Wednesday. Alcobra has a 52 week low of $0.83 and a 52 week high of $2.68. The firm’s market capitalization is $28.94 million. The firm’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.11.
Alcobra (NASDAQ:ADHD) last announced its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. On average, analysts anticipate that Alcobra will post ($0.50) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2017/10/08/alcobra-ltd-adhd-raised-to-buy-at-zacks-investment-research.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of ADHD. Royce & Associates LP raised its holdings in Alcobra by 15.5% during the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock valued at $849,000 after buying an additional 100,000 shares in the last quarter. Citadel Advisors LLC raised its holdings in Alcobra by 7,251.0% during the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 101,514 shares in the last quarter. Finally, Worth Venture Partners LLC raised its holdings in Alcobra by 35.6% during the second quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 71,465 shares in the last quarter. Institutional investors own 29.68% of the company’s stock.
Alcobra Company Profile
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.